成人视频色情片

Skip to main content Skip to search
""

M.S. in Biotechnology Management and Entrepreneurship

Making the World Smarter, Safer and Healthier

""

Eligible for

STEM-OPT
""
""

Affordable Fixed-Rate Tuition

$30K
After STEM Fellows Scholarship
""
""

QS Rankings

#63
University in the U.S.
""
""

Alumni Career Outcomes

95%
employed within 6 months
""

M.S. in Biotechnology Management & Entrepreneurship

12 Courses  I  On-Campus in New York City  I  Full-Time or Part-Time 

The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You鈥檒l learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Program Highlights

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem.

Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs.

95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics.

Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News.

STEM-OPT: International students may be eligible for up to 3 years of Optional Practical Training (OPT).  

$30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health

Full Program Breakdown

M.S. in Biotechnology Management & Entrepreneurship

12 Courses  I  On-Campus in New York City  I  Full-Time or Part-Time 

The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You鈥檒l learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Program Highlights

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem.

Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs.

95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics.

Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News.

STEM-OPT: International students may be eligible for up to 3 years of Optional Practical Training (OPT).  

$30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health

Swipe to learn more!

M.S. in Biotechnology Management & Entrepreneurship

12 Courses  I  On-Campus in New York City  I  Full-Time or Part-Time 

The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You鈥檒l learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem.

Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs.

95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics.

Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News.

STEM-OPT: International students may be eligible for up to 3 years of Optional Practical Training (OPT).  

$30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health

Graduate Admissions

General Inquiries

Join our Community

Application Information 

Candidates must possess a bachelor's degree from an accredited college or university.

Visit Graduate Admissions for up-to-date application requirements and deadlines. 

Questions? 鈥痠f you have questions about your qualifications, financial aid opportunities鈥痑nd financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.鈥

B.A./M.S. Pathways Option

Through the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelor鈥檚 and master's degrees. After completing the bachelor鈥檚, students can finish the graduate degree in just one more year. Learn more at yu.edu/pathways.

Tuition, Financial Aid and Scholarships 

The Office of Student Finance maintains current tuition and fees for all graduate programs.  

All applicants are automatically considered for the  program. You do not need to submit any additional information. 

Learn More

Graduate Admissions

General Inquiries

Join our Community

Admissions & Financial Aid

Application Information 

Candidates must possess a bachelor's degree from an accredited college or university.

Visit Graduate Admissions for up-to-date application requirements and deadlines. 

Questions? 鈥痠f you have questions about your qualifications, financial aid opportunities鈥痑nd financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.鈥

B.A./M.S. Pathways Option

Through the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelor鈥檚 and master's degrees. After completing the bachelor鈥檚, students can finish the graduate degree in just one more year. Learn more at yu.edu/pathways.

Tuition, Financial Aid and Scholarships 

The Office of Student Finance maintains current tuition and fees for all graduate programs.  

All applicants are automatically considered for the  program. You do not need to submit any additional information. 

Meet our Students

Christine Chery '25 on the Commercialization Potential for Novel Cancer Treatment JunAP

Developed by Sapience Therapeutics, Inc., JunAP is a cutting-edge peptide antagonist that inhibits the AP-1 transcription factor complex, a key player in oncogenesis and immune suppression.

""

Natania Birnbaum '24 on Duckweed's Potential for Sustainable, Space-Based Food Production

Duckweed is a small, fast-growing, nutritionally dense aquatic plant that鈥檚 being investigated for human consumption and for growing in outer space. Under the guidance of professor Robert Friedman and industry mentor John McShane, MS '21, Natania conducted a comprehensive survey of duckweed biology, genetics, and cultivation methods and charted the current economic landscape and future projections for the duckweed market.

Meet the Faculty

Dr. Oliveira is Advancing Medical Technologies with the Power of Marine Bioluminescent Enzymes

From deep-sea bioluminescence to antifreeze proteins, Dr. Anderson Garbuglio de Oliveira's trailblazing research is set to advance disease detection, allowing for earlier diagnoses and improved patient outcomes.

""

Dr. Jochen Raimann's Cutting-Edge Epidemiological Research in Dialysis

Industry professor of biotechnology, Dr. Raimann, has been a full-time scientist at the Renal Research Institute (RRI) since 2007. As RRI's director of data analytics, he conducts epidemiological research in dialysis, oversees research database management and national and international data transfers.

Program News

""

Biotech Alum Explores Hydroponic Space Greens

Read more about Natania Birnbaum's research

Biotech Alum Explores Hydroponic Space Greens

Natania Birnbaum, a 2024 graduate of the M.S. in Biotechnology Management and Entrepreneurship, conducted a comprehensive survey of the available literature on duckweed biology, genetics and cultivation methods, as well as an investigation into the major companies in the industry and economic projections for the future of the duckweed market.

Read the story in the Katz School blog.

""

Researchers Develop Algorithms to Assist in Stroke Recovery

Read about the study

Researchers Develop Algorithms to Assist in Stroke Recovery

Researchers have developed a series of algorithms using Siamese networks, a type of artificial intelligence, to better identify and track the body movements of stroke patients in order to assist in patient treatment and recovery. 

Read about the story in the Katz School blog.

""

Weill Cornell, Biotech Highlights Graduate Student Research

Read about the research

Weill Cornell, Biotech Highlights Graduate Student Research

Collaborations, like the one between Weill Cornell Medicine and the Katz School鈥檚 M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. 

Read the story in the Katz School blog.

""

Less Dietary Sodium Key to Protecting Kidney Disease Patients

Read about the paper's results

Less Dietary Sodium Key to Protecting Kidney Disease Patients

Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.

Read about the story in the Katz School blog.

""

Alum's Kit Tests for Miscarriage Causes

Read more about Rebecca's product idea

Alum's Kit Tests for Miscarriage Causes

Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossberg鈥檚 test would be important because individuals who miscarry in their first trimester typically do so at home and thus don鈥檛 have the opportunity to genetically test the fetal tissue to determine a cause.

Read the entire story here.

""

Biotech Professor Writes Book on Innovation

Read about what inspired Lorraine Marchand

Biotech Professor Writes Book on Innovation

In The Innovation Mindset, Lorraine Marchand shares her , a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.

.

SUMO protein

Students Targeting SUMO Proteins in Male Infertility

Read about the YU-Katz Biotech research partnership

Students Targeting SUMO Proteins in Male Infertility

A 成人视频色情片 researcher and several Katz School graduate students will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YU鈥檚 Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.

Read entire story on the Katz blog.

Shanza

Sloan Kettering Hires Biotechnology Graduate

Read more about Shanza Tariq's experience

Sloan Kettering Hires Biotechnology Graduate

When Shanza Baseer Tariq graduated in May with a master鈥檚 degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.

.

peptides

Market Analysis Finds Commercial Promise for Cancer Drug

Read more about the research

Market Analysis Finds Commercial Promise for Cancer Drug

Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. 

The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. 

In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. 

He found that colorectal cancer patients would be a prime population for Sapience鈥檚 novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. 鈥淐olorectal cancer presents the highest upside according to the revenue projection model,鈥 said Strauss, who is a healthcare consultant for the Marwood Group, 鈥渁nd presents the largest potential available population among the five cancer types studied.鈥 

Sapience鈥檚 therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system鈥檚 response to cancerous tumors. The interactions targeted by Sapience are considered 鈥渦ndruggable鈥 due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. 

鈥淧eptides combine the best properties of small and large molecules,鈥 said Dr. Kappel, 鈥渁nd present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.鈥 

Robert Friedman, an adjunct professor in the biotechnology program and Strauss鈥檚 advisor, said that Strauss鈥檚 presentation demonstrates the strength of the 鈥渕olecule-to-market nature鈥 of the Katz School鈥檚 biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. 

鈥淎vi鈥檚 understanding of the science, clinical development and the market were all critical to successfully completing the project,鈥 he said. 鈥淭he piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.鈥

""

New York City a Hub for Biotech Innovation

Read more about the city's $500 million investment

New York City a Hub for Biotech Innovation

Four of the top 10 biopharma clusters are located in the New York area. New York City鈥檚 Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. 

From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people.  

Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master鈥檚 in biotechnology management and entrepreneurship. 

""

Biotech Alum Explores Hydroponic Space Greens

Read more about Natania Birnbaum's research

Biotech Alum Explores Hydroponic Space Greens

Natania Birnbaum, a 2024 graduate of the M.S. in Biotechnology Management and Entrepreneurship, conducted a comprehensive survey of the available literature on duckweed biology, genetics and cultivation methods, as well as an investigation into the major companies in the industry and economic projections for the future of the duckweed market.

Read the story in the Katz School blog.

""

Researchers Develop Algorithms to Assist in Stroke Recovery

Read about the study

Researchers Develop Algorithms to Assist in Stroke Recovery

Researchers have developed a series of algorithms using Siamese networks, a type of artificial intelligence, to better identify and track the body movements of stroke patients in order to assist in patient treatment and recovery. 

Read about the story in the Katz School blog.

""

Weill Cornell, Biotech Highlights Graduate Student Research

Read about the research

Weill Cornell, Biotech Highlights Graduate Student Research

Collaborations, like the one between Weill Cornell Medicine and the Katz School鈥檚 M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. 

Read the story in the Katz School blog.

""

Less Dietary Sodium Key to Protecting Kidney Disease Patients

Read about the paper's results

Less Dietary Sodium Key to Protecting Kidney Disease Patients

Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.

Read about the story in the Katz School blog.

""

Alum's Kit Tests for Miscarriage Causes

Read more about Rebecca's product idea

Alum's Kit Tests for Miscarriage Causes

Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossberg鈥檚 test would be important because individuals who miscarry in their first trimester typically do so at home and thus don鈥檛 have the opportunity to genetically test the fetal tissue to determine a cause.

Read the entire story here.

""

Biotech Professor Writes Book on Innovation

Read about what inspired Lorraine Marchand

Biotech Professor Writes Book on Innovation

In The Innovation Mindset, Lorraine Marchand shares her , a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.

.

SUMO protein

Students Targeting SUMO Proteins in Male Infertility

Read about the YU-Katz Biotech research partnership

Students Targeting SUMO Proteins in Male Infertility

A 成人视频色情片 researcher and several Katz School graduate students will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YU鈥檚 Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.

Read entire story on the Katz blog.

Shanza

Sloan Kettering Hires Biotechnology Graduate

Read more about Shanza Tariq's experience

Sloan Kettering Hires Biotechnology Graduate

When Shanza Baseer Tariq graduated in May with a master鈥檚 degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.

.

peptides

Market Analysis Finds Commercial Promise for Cancer Drug

Read more about the research

Market Analysis Finds Commercial Promise for Cancer Drug

Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. 

The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. 

In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. 

He found that colorectal cancer patients would be a prime population for Sapience鈥檚 novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. 鈥淐olorectal cancer presents the highest upside according to the revenue projection model,鈥 said Strauss, who is a healthcare consultant for the Marwood Group, 鈥渁nd presents the largest potential available population among the five cancer types studied.鈥 

Sapience鈥檚 therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system鈥檚 response to cancerous tumors. The interactions targeted by Sapience are considered 鈥渦ndruggable鈥 due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. 

鈥淧eptides combine the best properties of small and large molecules,鈥 said Dr. Kappel, 鈥渁nd present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.鈥 

Robert Friedman, an adjunct professor in the biotechnology program and Strauss鈥檚 advisor, said that Strauss鈥檚 presentation demonstrates the strength of the 鈥渕olecule-to-market nature鈥 of the Katz School鈥檚 biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. 

鈥淎vi鈥檚 understanding of the science, clinical development and the market were all critical to successfully completing the project,鈥 he said. 鈥淭he piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.鈥

""

New York City a Hub for Biotech Innovation

Read more about the city's $500 million investment

New York City a Hub for Biotech Innovation

Four of the top 10 biopharma clusters are located in the New York area. New York City鈥檚 Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. 

From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people.  

Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master鈥檚 in biotechnology management and entrepreneurship. 

Skip past mobile menu to footer